Synapse - Saad Usmani

Results (328)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

Journal Article

Usmani, S. Z.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D.; Weisel, K.; Shu, X.; Li, C.; Dimopoulos, M.
Blood Advances (2023)

Fulltext@MSK | Save

Extrapolation of survival data using a Bayesian approach: A case study leveraging external data from cilta-cel therapy in multiple myeloma

Journal Article

Palmer, S.; Lin, Y.; Martin, T. G.; Jagannath, S.; Jakubowiak, A.; Usmani, S. Z.; Buyukkaramikli, N.; Phelps, H.; Slowik, R.; Pan, F.; more...
Oncology and Therapy (2023)

Fulltext@MSK | Save

Patient perceptions regarding ciltacabtagene autoleucel treatment: Qualitative evidence from interviews with patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study

Journal Article

Cohen, A. D.; Hari, P.; Htut, M.; Berdeja, J. G.; Usmani, S. Z.; Madduri, D.; Olyslager, Y.; Goldberg, J. D.; Schecter, J. M.; Jackson, C. C.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: A prospective, observational study

Research Letter

Dhakal, B.; Zhang, M. J.; Burns, L. J.; Tang, X.; Meyer, C.; Mau, L. W.; Nooka, A. K.; Stadtmauer, E.; Micallef, I. N.; McGuirk, J.; more...
Haematologica (2023)

Fulltext@MSK | Save

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Journal Article

Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
Blood Cancer Journal (2023)

Fulltext@MSK | Save

Global disparities in patients with multiple myeloma: A rapid evidence assessment

Journal Article

Mateos, M. V.; Ailawadhi, S.; Costa, L. J.; Grant, S. J.; Kumar, L.; Mohty, M.; Aydin, D.; Usmani, S. Z.
Blood Cancer Journal (2023)

Fulltext@MSK | Save

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: A CIBMTR analysis

Journal Article

Ragon, B. K.; Shah, M. V.; D’Souza, A.; Estrada-Merly, N.; Gowda, L.; George, G.; de Lima, M.; Hashmi, S.; Kharfan-Dabaja, M. A.; Majhail, N. S.; more...
Blood Advances (2023)

Fulltext@MSK | Save

Radiation in a new era of multiple myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of response

Meeting Abstract

Dreyfuss, A. D.; Fregonese, B.; Ma, J.; Reith, S.; Cederquist, G.; Hubbeling, H.; Tringale, K. R.; Wijetunga, N. A.; Usmani, S.; Hajj, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

A clinical and correlative study of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for lenalidomide refractory multiple myeloma in first relapse